Imagyn Medical Inc.: Building a Market Franchise in Women's Health
Executive Summary
Imagyn faces problems common to small device companies: a daunting FDA, less lucrative end-markets, and lack of effective distribution. Short-term it’s betting on US Surgical to market its products. Longer-term it hopes to grow by building a portfolio of products that move gynecological and infertility procedures out of the hospital.
You may also be interested in...
US FDA Mum On Whether Woodcock Would Stick Around Long-Term For Califf
Woodcock’s willingness to stay on at US FDA for more than a transitional period after Robert Califf’s expected confirmation as commissioner may depend on exactly the type of authority and tasks he’d be willing to delegate to her. Plus, some other agency personnel updates.
USP Nitrosamine Impurities Chapter Reflects Careful Coordination With US, EU Authorities
The USP’s general chapter on nitrosamine impurities provides guidance on assessing risks and testing levels of the carcinogens in pharmaceuticals.
ASH Preview: Three Areas To Watch In Hematology-Oncology
Novartis hopes a CAR-T with rapid manufacturing will be a winner, while novel bispecific antibodies in lymphoma and myeloma will make appearances, along with next-generation PI3K and BTK inhibitors.